Top of this page
Skip navigation, go straight to the content
Let’s get to know each other
At UCB, we’re dedicated to developing innovative solutions for those living with and managing immuno-dermatological conditions, but we cannot do it alone.
Our aim is to partner with people like you in an effort to make a meaningful impact on patients’ lives. Because we believe that together, we can make a difference.
A bit about us
UCB is committed to communicating science simply, bridging provider and patient connectivity, and engaging authentically with the dermatology community. In our
90-plus-year history, we have developed breakthrough medicines for neurological and immunological conditions.
EVERYTHING WE DO STARTS WITH ONE SIMPLE QUESTION:
“How will this create value for people living with severe diseases?”
We are excited to get to know you, too, and determine where our passions for moving dermatology forward intersect.
Tell us, “What difference do you want to see for your patients with immuno-dermatological conditions?”
We are committed to dermatology
We are pursuing pioneering research to deliver innovative solutions to improve the lives of those living with chronic conditions.
“We celebrate people like you who share our commitment to advancing the discussion, understanding, and treatment of immuno-dermatological conditions.”
- Rhonda Peebles, Head of US Dermatology
Patients are our reason for being
We go beyond the science to provide an exceptional patient experience for people with immuno-dermatological disease, whether they seek product-related information, financial support, or a real connection with someone like them.
“Our history of transforming science into health-changing treatment solutions that improve patients’ lives is something I’m extremely
proud of.”
- Camille Lee, Head of US Immunology
We pride ourselves in patient-centered research
~25% of our revenue is reinvested every year in research and development to find solutions for unmet patient needs.
“Our approach—from discovery to development to delivery—is continuously transformed and designed around patient needs and
their journey.”
- Tae Oh, Medical Affairs Lead, Dermatology
Let’s talk about you
We are invested in the dermatology community and strive to partner with and support you in meaningful ways. We look forward to getting to know you, learn from you, and listen to your needs and those of your patients and colleagues to truly make an impact.
TO GET THE CONVERSATION STARTED, WE ASK YOU:
“What difference would you like to see for your patients with immuno-dermatological conditions?”
A strong foundation
Learn more about the scientific breakthroughs, treatment advances, and partnerships that demonstrate and affirm UCB’s continued ambition to transform the lives of people living with severe diseases.
Continuing our 90-plus-year history of partnering to improve the patient experience through scientific solutions
Prescribing Information
- Keppra® (levetiracetam) injection
Full Prescribing Information and Medication Guide - Keppra® (levetiracetam) tablets and oral solution
Full Prescribing Information and Medication Guide - Keppra XR® (levetiracetam)
Full Prescribing Information and Medication Guide - Briviact® (brivaracetam) CV
Full Prescribing Information - Cimzia® (certolizumab pegol)
Full Prescribing Information - Nayzilam® (midazolam) nasal spray CIV
Full Prescribing Information - Neupro® (rotigotine transdermal system)
Full Prescribing Information - Vimpat® (lacosamide) CV
Full Prescribing Information
Briviact®, Cimzia®, Keppra XR®, Keppra®, Nayzilam® and Neupro® are registered trademarks of the UCB Group of Companies. Vimpat® is a registered trademark used under license from Harris FRC Corporation.
Our future in immuno-dermatology starts
with you
We are listening so we can best serve the needs of the dermatology community. By working together today, we will improve the lives of patients tomorrow.
TELL US
“What would you like to see UCB accomplish as we enter the next decade of dermatology?”
At UCB, innovation is ongoing through our commitment to find solutions to meet the unmet needs of patients. Read through our latest news releases, and subscribe to receive updates.
US-P-DA-PSO-2000062